US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neo-Concept International Group Holdings Limited

0.3101

+0.00993.30%

Volume:48.97K

Turnover:15.48K

Market Cap:6.30M

PE:4.06

High:0.3499

Open:0.3103

Low:0.3002

Close:0.3002

Loading ...

Overview Company News Filings

Shell announces commencement of a share buyback programme

Press Release: Shell plc First Quarter 2025 Interim Dividend

Shell plc publishes first quarter 2025 press release

DMC Global Reports First Quarter Financial Results

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

ORYZON Raises €30 Million in Capital Increase

Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin

ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Preliminary results for the year ended 31 December 2024

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

ACCESS Newswire

Shell first quarter 2025 update note

Press Release: Shell to sell interest in Colonial Enterprises Inc. to Brookfield subsidiary

Neo-Concept International Launches Les100Ciels Store in Abu Dhabi: A New Chapter in MENA!

Press Release: QT Imaging Announces Fourth Quarter and Full Year 2024 Financial Results and Provides 2025/26 Outlook

Press Release: Aptose Reports Year End 2024 Results and Corporate Highlights

Press Release: Tempest Reports Year End 2024 Financial Results and Provides Business Update

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NCI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":0.3101,"timestamp":1746216000000,"preClose":0.3002,"halted":0,"volume":48974,"delay":0,"floatShares":1726200,"shares":20320000,"eps":0.076408,"marketStatus":"Post-Mkt","change":0.0099,"latestTime":"05-02 16:30:21 EDT","open":0.3103,"high":0.3499,"low":0.3002,"amount":15480.333371,"amplitude":0.165556,"askPrice":0.35,"askSize":20000,"bidPrice":0.2927,"bidSize":100,"shortable":0,"etf":0,"ttmEps":0.076408,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746230400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":0.3002,"dividendRate":0.644953,"preHourTrading":{"tag":"盘前","latestPrice":0.297,"preClose":0.3301,"latestTime":"09:27 EDT","volume":1100,"amount":329.34,"timestamp":1746192470100},"volumeRatio":0.839766},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":1726200,"roa":"6.28%","roe":"58.31%","lyrEps":0.031396,"volumeRatio":0.839766,"shares":20320000,"dividePrice":0.2,"high":0.3499,"amplitude":0.165556,"preClose":0.3002,"low":0.3002,"week52Low":0.28,"pbRate":"0.98","psRate":"0.28","week52High":1.8,"institutionHeld":0.7857,"latestPrice":0.3101,"committee":-0.99005,"eps":0.076408,"divideRate":0.644953,"volume":48974,"delay":0,"ttmEps":0.076408,"open":0.3103,"prevYearClose":0.66,"prevWeekClose":0.37,"prevMonthClose":0.3446,"prevQuarterClose":0.48,"fiveDayClose":0.37,"twentyDayClose":0.448,"sixtyDayClose":0.5561},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532898794","title":"Shell announces commencement of a share buyback programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2532898794","media":"GlobeNewswire","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532898794?lang=en_us&edition=fundamental","pubTime":"2025-05-02 14:03","pubTimestamp":1746165780,"startTime":"0","endTime":"0","summary":"Shell plc  today announces the commencement of a $3.5 billion share buyback programme covering an aggregate contract term of approximately three months . The purpose of the programme is to reduce the issued share capital of the Company. All shares repurchased as part of the programme will be cancelled. It is intended that, subject to market conditions, the programme will be completed prior to the Company’s Q2 2025 results announcement, scheduled for July 31, 2025.The maximum number of ordinary shares which may be purchased or committed to be purchased by the Company under the programme  is 320,000,000, which is the maximum number remaining as of the date of this announcement pursuant to the relevant authorities granted by shareholders at the Company's 2024 Annual General Meeting.The broker will make its trading decisions in relation to the Company's securities independently of the Company.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shell-announces-commencement-share-buyback-060300272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0278409577.USD","BK4585","LU0300736492.USD","LU2236285917.USD","NCI","SHEL","LU0300736062.USD","LU0320765646.SGD","BK4588","BK4156","BK4202","LU1162221912.USD","LU0098860793.USD","BK4201"],"gpt_icon":0},{"id":"2532671288","title":"Press Release: Shell plc First Quarter 2025 Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2532671288","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532671288?lang=en_us&edition=fundamental","pubTime":"2025-05-02 14:02","pubTimestamp":1746165720,"startTime":"0","endTime":"0","summary":"London, May 2, 2025 - The Board of Shell plc   today announced an interim dividend in respect of the first quarter of 2025 of US$ 0.358 per ordinary share.Details relating to the first quarter 2025 interim dividend. Shareholders will be able to elect to receive their dividends in US dollars, euros or pounds sterling.An alternative 'Electronic Election Entitlement'  process is available in CREST for dividends with options elections.Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros.Absent any valid election to the contrary, shareholders  and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling.Each ADS represents two ordinary shares. ADSs are evidenced by an American Depositary Receipt  certificate. In many cases the terms ADR and ADS are used interchangeably.Dividend timetable for the first quarter 2025 interim dividend. The followi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0098860793.USD","NCI","BK4202","BK4201","LU0320765646.SGD","LU2236285917.USD","BK4588","BK4585","LU1162221912.USD","LU0278409577.USD","SHEL","LU0300736492.USD","LU0300736062.USD"],"gpt_icon":0},{"id":"2532898797","title":"Shell plc publishes first quarter 2025 press release","url":"https://stock-news.laohu8.com/highlight/detail?id=2532898797","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532898797?lang=en_us&edition=fundamental","pubTime":"2025-05-02 14:01","pubTimestamp":1746165660,"startTime":"0","endTime":"0","summary":"\"Shell delivered another solid set of results in the first quarter of 2025. We further strengthened our leading LNG business by completing the acquisition of Pavilion Energy, and high-graded our portfolio with the completion of the Nigeria onshore and the Singapore Energy and Chemicals Park divestments.Our strong performance and resilient balance sheet give us the confidence to commence another $3.5 billion of buybacks for the next three months, consistent with the strategic direction we set out at our Capital Markets Day in March.\". Q1 2025 Adjusted Earnings1 of $5.6 billion reflect strong performance across the business. CFFO excluding working capital was $11.9 billion for the quarter. Working capital outflow was $2.7 billion in Q1 2025.Strengthened LNG trading and optimisation capabilities with the Pavilion Energy acquisition and high-graded the portfolio with the completion of the divestments of the Singapore Energy and Chemicals Park2, and SPDC3 in Nigeria.Disciplined capital allo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shell-plc-publishes-first-quarter-060100623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4561","BK4585","NCI","BK4006","LU0300736062.USD","LU0098860793.USD","LU1162221912.USD","LU0320765646.SGD","LU2236285917.USD","BK4201","LU0300736492.USD","MT","BK4202","SHEL","LU0278409577.USD","BK4588"],"gpt_icon":0},{"id":"2532388020","title":"DMC Global Reports First Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532388020","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532388020?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:05","pubTimestamp":1746129900,"startTime":"0","endTime":"0","summary":"First quarter sales were $159.3 million, up 5% sequentially and down 5% versus Q1 2024. Sales at Arcadia, DMC’s architectural building products business, were $65.6 million, up 9% sequentially and up 6% versus last year’s first quarter. The growth reflects higher sales of commercial exterior store front products and interior framing systems, which more than offset an expected decline in high-end residential window and door sales. Arcadia has recently refocused on its core commercial operations while making cost control a priority in the current volatile macroeconomic environment. Adjusted EBITDA attributable to DMC was $5.6 million, up 149% sequentially and up 58% versus the prior-year first quarter.At DynaEnergetics, DMC’s energy products business, first quarter sales were $65.6 million, up 3% sequentially and down 16% versus the year-ago first quarter. The year-over-year decline principally reflects pricing adjustments and lower unit sales associated with weakness in the highly volat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dmc-global-reports-first-quarter-200500938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","BK4179","BK4202","BOOM"],"gpt_icon":0},{"id":"2529128986","title":"NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD","url":"https://stock-news.laohu8.com/highlight/detail?id=2529128986","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529128986?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:01","pubTimestamp":1745496060,"startTime":"0","endTime":"0","summary":"Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing. The study was conducted by investigators at Case Western Reserve University  and University Hospitals  and enrolled patients without GERD symptoms who otherwise met AGA recommendations for BE screening. EsoGuard demonstrated excellent negative predictive value  of 100% for detecting esophageal precancer, consistent with its unprecedented precancer detection reported across multiple peer-reviewed clinical validity studies in patients with symptomatic GERD. The study also showed a BE prevalence of 8.4%, a rate comparable to the established prevalence in patients with symptomatic GERD. The manuscript, entitled Nonendoscopic Detection of Barrett's Esophagus in Patients Without GERD Symptoms, is currently available on the leading health sciences preprint server, MedRxiv, and has been submitted for peer-reviewed publication.About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nci-sponsored-study-shows-positive-120100152.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nci-sponsored-study-shows-positive-120100152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4555","BK4596","NCI","LUCD","BK4099","DNA","BK4109","BK4202","PAVMZ","LCID","BK4551","PAVM","NPV","BK4139"],"gpt_icon":0},{"id":"2529986144","title":"ORYZON Raises €30 Million in Capital Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2529986144","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529986144?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496000,"startTime":"0","endTime":"0","summary":"Priced at 2.35 per share, representing a 15.44% discount on the 5-day VWAP. Strong investor demand, with the offering significantly oversubscribed. 15 million anchored by a leading US institutional investor. Proceeds to fund clinical development and corporate initiatives. Maxim , All-Invest , and Singular Bank  acted as bookrunners. Banco Sabadell, S.A. acted as the Settlement and Technical Pre-financing Agent for the Capital Increase, while Gómez-Acebo & Pombo Abogados, S.L.P.  and Gibson, Dunn & Crutcher LLP  served as legal advisors to the Company, and Loeb & Loeb LLP acted as U.S. legal counsel to Maxim Group LLC.About OryzonFounded in 2000 in Barcelona, Spain, Oryzon  is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oryzon-raises-30-million-capital-120000514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4127","LU1162221912.USD","LU0158827948.USD","BK4548","LU2357305700.SGD","LU1720051017.SGD","BK4560","LU1989772840.SGD","BK4202","LU0225283273.USD","LU2023251221.USD","BK4613","LU1732800096.USD","BK4588","LU0158827781.USD","NCI","BK4585","LU2111349929.HKD","BK4504","LU2286300806.USD","BK4581","LU1668664300.SGD","LU0795875169.SGD","BK4534","ORYZF","LU1548497426.USD","LU1732799900.SGD","BK4607","LU0971096721.USD","BK4156","LU2028103732.USD","LU2133065610.SGD","BK4554","LU1074936037.SGD","LU1720051108.HKD","BK4116","LU0006306889.USD","BK4139","LU2089284900.SGD","LU0320765646.SGD","BK4516","NET","LU0106831901.USD","IE00BKVL7J92.USD","LU0795875086.SGD","LU1363072403.SGD","LU1989772923.USD","LU0314104364.USD","LU2271345857.HKD"],"gpt_icon":0},{"id":"2529569508","title":"Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin","url":"https://stock-news.laohu8.com/highlight/detail?id=2529569508","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529569508?lang=en_us&edition=fundamental","pubTime":"2025-04-24 07:00","pubTimestamp":1745449200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, April 23, 2025  -- Ascentage Pharma , a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that results from two clinical studies of the Bcl-2 selective inhibitor lisaftoclax  and the MDM2-p53 inhibitor alrizomadlin , two key drug candidates in the company’s apoptosis-targeted pipeline, have been selected for presentations at the 2025 American Society of Clinical Oncology  Annual Meeting. These presentations will include an oral report featuring updated results from a Phase Ib/II study of a lisaftoclax combination regimen in patients with myeloid malignancies.The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the clinical oncology community, bringing togethe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascentage-pharma-present-data-two-230000349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AAPG","NCI","BK4139","BK4202"],"gpt_icon":0},{"id":"2527413733","title":"ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527413733","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527413733?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"Study conducted under the CRADA agreement between NCI and Oryzon. MADRID and CAMBRIDGE, Mass., April 15, 2025  -- Oryzon Genomics, S.A. , a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in a Phase I/II trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with immune checkpoint inhibitors  in first line small cell lung cancer  patients with extensive disease, sponsored by the National Cancer Institute , part of the National Institutes of Health. This is the first clinical trial testing the combination of iadademstat with ICI.About OryzonFounded in 2000 in Barcelona, Spain, Oryzon  is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oryzon-announces-first-patient-dosed-120000598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORYZF","BK4156","BK4613","BK4202","NET","BK4554","BK4560","NCI","BK4585","BK4607","SSI","BK4588","LU2286300806.USD","BK4548","BK4116","BK4139"],"gpt_icon":0},{"id":"2527163224","title":"Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2527163224","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527163224?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:30","pubTimestamp":1744716600,"startTime":"0","endTime":"0","summary":"New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ. Finally, RNA sequencing of LM cells showed early induction of apoptosis, with an innate immune response followed by an increase in T cells and an adaptive immune response by Day 28. Further details can be found here; the Company will provide additional data and explanation following the meeting.About Leptomeningeal Metastases LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid  and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3-5% of breast cancer patients developing LM. Additionally, lung cancer, GI cancers and melanoma can also spread to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/plus-therapeutics-presents-data-highlighting-113000997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","CSF","BK4135","BK4007","BK4202","PSTV","LENZ","BK4139","CNS"],"gpt_icon":0},{"id":"2526498953","title":"Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2526498953","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526498953?lang=en_us&edition=fundamental","pubTime":"2025-04-10 04:30","pubTimestamp":1744230600,"startTime":"0","endTime":"0","summary":"Amezalpat  is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma ; global investigator support in place. Awarded both Orphan Drug & Fast Track designations for amezalpat based on positive randomized Phase 2 data in first-line HCC. Received FDA “Study May Proceed” letter for TPST-1495 in a Phase 2 trial for the treatment of familial adenomatous polyposis ; data expected 2026. The company has not set a timetable for completion of the process for evaluating strategic alternatives and does not intend to disclose further developments or guidance on the status of its programs or the process for evaluating strategic alternatives unless and until it is determined that further disclosure is appropriate or necessary. No agreement providing for any transaction has been reached and there can be no assurances that any transaction will result from the process for evaluating strategic alternatives. If the process for evaluating strategic alterna","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempest-announces-plan-explore-strategic-203000016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4006","HCC","BK4097","NCI","OS","BK4202","TPST"],"gpt_icon":0},{"id":"2526352564","title":"Preliminary results for the year ended 31 December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2526352564","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526352564?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:00","pubTimestamp":1744196400,"startTime":"0","endTime":"0","summary":"~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of 44% to 128.8 million compared to 2023, organic r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/09/3058256/0/en/Preliminary-results-for-the-year-ended-31-December-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4019","BK4229","BK4159","NCI","CAGR","CET","CDMO","AGM","ESGR","CFO","BK4139","BK4202","BK4195"],"gpt_icon":0},{"id":"2525092892","title":"Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2525092892","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525092892?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:30","pubTimestamp":1744115400,"startTime":"0","endTime":"0","summary":"Gelclair is the company's third commercialized prescription product. Oral mucositis, also called \"chemo mouth,\" a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force. Napo's core target patient audiences for Gelclair are head and neck cancer patients and bone marrow transplant patients. \"Cancer is chaotic, because patients feel a loss of control - over their life, their treatment, and their supportive care needs,\" said Conte. \"Jaguar's mission is to change patients' lives for the better, especially in the area of supportive care for complex disease states like cancer. We look forward to driving awareness among the oncology nursing community at ONS about Gelclair. Oral mucositis, also called \"chemo mouth,\" is among the most common, painful, and debilitating cancer treatment-related side effects, and it is undertreated and underappreciated. We believe we can hel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/napo-pharmaceuticals-jaguar-health-family-123000734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","BK4007","BK4202","JAGX"],"gpt_icon":0},{"id":"2525063796","title":"Shell first quarter 2025 update note","url":"https://stock-news.laohu8.com/highlight/detail?id=2525063796","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525063796?lang=en_us&edition=fundamental","pubTime":"2025-04-07 14:00","pubTimestamp":1744005600,"startTime":"0","endTime":"0","summary":"The following is an update to the first quarter 2025 outlook and gives an overview of our current expectations for the first quarter. Outlooks presented may vary from the actual first quarter 2025 res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056424/0/en/Shell-first-quarter-2025-update-note.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4202","MT","BK4561","NCI"],"gpt_icon":0},{"id":"2524727468","title":"Press Release: Shell to sell interest in Colonial Enterprises Inc. to Brookfield subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2524727468","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524727468?lang=en_us&edition=fundamental","pubTime":"2025-04-04 17:34","pubTimestamp":1743759240,"startTime":"0","endTime":"0","summary":"HOUSTON, April 3, 2025 /PRNewswire/ -- Shell Midstream Operating LLC. , a subsidiary of Shell plc , has agreed to sell its. AcquireCo LLC, a wholly owned subsidiary of Brookfield Infrastructure. \"This divestment reflects our focus on performance, discipline and. simplification,\" said Andrew Smith, President of Shell Trading & Supply.\"It will allow us to concentrate on areas where we have scale and. The transaction is subject to regulatory approvals and is expected to. -- Together with Shell, the co-owners of Colonial Enterprises, Inc. have. agreed to sell 100% of their Colonial shares to Brookfield. Colonial is. -- The sale values Shell's share of Colonial at $1.45 billion, inclusive of. -- Shell Midstream Operating LLC is an indirect, wholly owned subsidiary of. Shell Pipeline Company LP, and the largest pipeline operator in the Gulf. and employs more than 12,000 people who work to provide a secure supply. Shell's U.S. portfolio of operated companies and interests consists of. The com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","LU0300736062.USD","LU0320765646.SGD","NCI","BK4550","BK4202","BK4208","BIP","SHEL","LU1162221912.USD","BK4585","LU0278409577.USD","LU2236285917.USD","BK4588","LU0098860793.USD","LU0300736492.USD"],"gpt_icon":0},{"id":"2524119809","title":"Neo-Concept International Launches Les100Ciels Store in Abu Dhabi: A New Chapter in MENA!","url":"https://stock-news.laohu8.com/highlight/detail?id=2524119809","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524119809?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:00","pubTimestamp":1743512400,"startTime":"0","endTime":"0","summary":"HONG KONG, April 01, 2025  -- Neo-Concept International Group Holdings Limited  is excited to announce the soft opening of its very first Les100Ciels store in the Middle East and North Africa  region!Located at The Galleria Al Maryah Island in Abu Dhabi, which took place on March 27, 2025.This milestone marks a significant leap forward in our journey, following the successful launch of our joint venture with Liwa Trading Enterprises LLC, designed to boost our retail footprint in the vibrant MENA markets.The debut of The Galleria store, coupled with our new Middle East e-shop, is a pivotal step in our mission to deliver an outstanding shopping experience—both online and in-store—for our customers in the MENA region.NCI is dedicated to minimizing its environmental footprint by implementing various eco-friendly practices. It prioritizes recycling, clean processes, and traceable sourcing as part of its commitment to reducing environmental imp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neo-concept-international-launches-les100ciels-130000750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4202","NCI"],"gpt_icon":0},{"id":"2523094952","title":"Press Release: QT Imaging Announces Fourth Quarter and Full Year 2024 Financial Results and Provides 2025/26 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2523094952","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523094952?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:33","pubTimestamp":1743424380,"startTime":"0","endTime":"0","summary":"Generated Sales of Twelve Scanners with Revenue of Approx. $5 Million and with 54% Gross Margin in 2024. Announced Insiders PIPE investment of $2.56 Million, fully funded by the QTI Board of Directors members and Management. Announced the Closing of $10.1 million Lynrock Lake Term Loan, of which $5.4 million is for Working Capital Purposes. Announced Clearing of All Its Short-Term Debt Liabilities. Closed Exclusive Distribution Agreement in USA with NXC Imaging. Entered into Manufacturing Agreement with Canon Medical Systems Corporation. Forecasts Solid Revenue Growth of $18 million and $27 million for 2025 and 2026, respectively. QT Imaging Holdings, Inc.  , a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the four quarter and full year 2024 and reiterated the strong forecast for 2025 and 2026.million for the fourth quarter of 2023. Commercial revenue was $4.9. million for the yea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTIH","BK4082","BK4202","BK4604","BK4099","NQmain","NCI","BK4585","TM","03160","BK4588","BK4555"],"gpt_icon":0},{"id":"2522432573","title":"Press Release: Aptose Reports Year End 2024 Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522432573","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522432573?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:01","pubTimestamp":1743163260,"startTime":"0","endTime":"0","summary":"Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial. Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy. SAN DIEGO and TORONTO, March 28, 2025  -- Aptose Biosciences Inc.  , a clinical-stage precision oncology company developing a tuspetinib -based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia , today announced financial results for the year ended December 31, 2024, and provided a corporate update.\"During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax  and azacitidine  for frontline treatment of newly diagnosed acute myeloid leukemia ,\" said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. \"Tuspetinib brings favorable safety and broad activity across AML genetic subtypes to the TUS+VEN+AZA triplet therapy, which already has achieved complete remissions  in difficult-to-t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","USAW.SI","QLD","LU2463526074.USD","SQQQ","NVIW.SI","APTOF","APTO",".IXIC","BK4139","BK4109","MNQmain","TQQQ","NCI","USJW.SI","TSYW.SI","QID","PSQ","NQmain","BK4202"],"gpt_icon":1},{"id":"2522853184","title":"Press Release: Tempest Reports Year End 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522853184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522853184?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:10","pubTimestamp":1743106200,"startTime":"0","endTime":"0","summary":"-- Granted Both Orphan Drug & Fast Track designations for Amezalpat  for the treatment of patients with Hepatocellular Carcinoma . -- Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial. -- Received FDA \"Study May Proceed\" letter for Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis . \"2024 was another year filled with significant progress and milestone achievements that position Tempest for a successful future,\" said Stephen Brady, president and chief executive officer of Tempest. \"Despite challenging capital markets, our lean team excelled, reporting key OS data from the ongoing randomized Phase 2 trial of amezalpat in first-line hepatocellular carcinoma. As previously announced, we have secured broad regulatory agreement with both the FDA and EMA on the Phase 3 plan and received both Orphan Drug and Fast Track designations from the FDA. We also advanced our second clinical program, TPST","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","TPST","BK4232","BK4202","HCC","OS","NCI","BK4097","BK4022","BK4006","BK4139"],"gpt_icon":0},{"id":"2522306967","title":"Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225","url":"https://stock-news.laohu8.com/highlight/detail?id=2522306967","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522306967?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:45","pubTimestamp":1743079500,"startTime":"0","endTime":"0","summary":"- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models. - ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model. - Initial ATNM-400 preclinical data to be presented at AACR including results in Pluvicto resistant prostate cancer models. ATNM-400 selectively binds to prostate cancer cells, undergoes rapid internalization, and induces dose-depen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-atnm-400-124500358.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-atnm-400-124500358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","NCI","HMA","ATNM","CR","BK4139","BK4202"],"gpt_icon":0},{"id":"2522615804","title":"Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522615804","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522615804?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:15","pubTimestamp":1742994900,"startTime":"0","endTime":"0","summary":"– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo –。– CABOMETYX is now the first and only systemic treatment that is FDA approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status –。– Exelixis is prepared to immediately support these new indications –。ALAMEDA, Calif., March 26, 2025----Exelixis, Inc.  today announced that the U.S. Food and Drug Administration  has approved CABOMETYX  for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors ; and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET . NET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-announces-u-fda-approval-131500269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","BK4532","BK4554","BK4585","IE00B19Z4B17.USD","BK4548","BK4560","DTC","NET","RCC","BK4202","AEIS","BK4588","BK4157","LU2286300806.USD","IE00B7SZL793.SGD","BK4139","BK4006","BK4116","EXEL","IE0031619046.USD","IE00B66KJ199.SGD","BK4607","BK4613","BK4190","HCC"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":96,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2025-05-01","current":4.935384,"percent":0.063025,"low":-615.963293,"twenty":6.301776,"median":15.60865,"eighty":24.382153,"high":50.080918,"avg":6.858719,"sd":52.260373,"marketCap":7002272},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":28.783514,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":16256000},{"date":"2024-06-07","current":28.579978,"twenty":-81.702314,"median":24.992177,"eighty":34.642796,"marketCap":16154400},{"date":"2024-06-14","current":31.815689,"twenty":-79.845114,"median":25.185699,"eighty":33.392506,"marketCap":17983200},{"date":"2024-06-21","current":25.826264,"twenty":-75.704037,"median":25.951163,"eighty":31.815689,"marketCap":14610080},{"date":"2024-06-28","current":24.010495,"twenty":-75.181642,"median":25.826264,"eighty":31.166365,"marketCap":13573760},{"date":"2024-07-05","current":21.847045,"twenty":-74.134092,"median":24.992177,"eighty":30.05711,"marketCap":12350496},{"date":"2024-07-12","current":24.005484,"twenty":-72.824666,"median":24.22361,"eighty":29.406809,"marketCap":13573760},{"date":"2024-07-15","current":23.309684,"twenty":-72.571072,"median":24.010495,"eighty":29.29759,"marketCap":13183616},{"date":"2024-08-02","current":17.799213,"twenty":-72.317479,"median":24.00799,"eighty":29.18837,"marketCap":10054336},{"date":"2024-08-09","current":15.712059,"twenty":-71.040839,"median":23.456094,"eighty":28.858081,"marketCap":8900160},{"date":"2024-08-16","current":14.71315,"twenty":-69.000048,"median":23.177414,"eighty":28.661392,"marketCap":8331200},{"date":"2024-08-23","current":15.475212,"twenty":-65.359249,"median":22.360574,"eighty":28.479131,"marketCap":8761984},{"date":"2024-08-30","current":15.211668,"twenty":-16.796281,"median":21.73132,"eighty":28.375818,"marketCap":8611616},{"date":"2024-09-06","current":15.60865,"twenty":14.533412,"median":17.564477,"eighty":28.127716,"marketCap":8839200},{"date":"2024-09-13","current":18.316746,"twenty":14.714645,"median":17.091682,"eighty":27.226945,"marketCap":10363200},{"date":"2024-09-20","current":30.136472,"twenty":14.729124,"median":17.451967,"eighty":27.226945,"marketCap":17068800},{"date":"2024-09-27","current":18.155945,"twenty":14.756986,"median":17.799213,"eighty":26.316487,"marketCap":10304272},{"date":"2024-10-04","current":24.668714,"twenty":14.779837,"median":18.134605,"eighty":27.226945,"marketCap":14022832},{"date":"2024-10-11","current":19.411936,"twenty":14.800605,"median":18.316746,"eighty":26.316487,"marketCap":11029696},{"date":"2024-10-18","current":27.159393,"twenty":14.841085,"median":19.188638,"eighty":26.316487,"marketCap":15422880},{"date":"2024-10-25","current":22.801653,"twenty":14.96086,"median":20.067961,"eighty":27.538745,"marketCap":12954000},{"date":"2024-10-31","current":26.444278,"twenty":15.097424,"median":21.615595,"eighty":28.23974,"marketCap":15016480},{"date":"2024-11-08","current":25.398607,"twenty":15.188698,"median":21.880614,"eighty":27.72766,"marketCap":14427200},{"date":"2024-11-15","current":22.207911,"twenty":15.214052,"median":22.207911,"eighty":27.409251,"marketCap":12598400},{"date":"2024-11-22","current":20.742686,"twenty":15.227723,"median":22.212919,"eighty":27.092873,"marketCap":11765280},{"date":"2024-11-29","current":19.71984,"twenty":15.244259,"median":22.031838,"eighty":26.826792,"marketCap":11184128},{"date":"2024-12-06","current":19.342155,"twenty":15.419442,"median":21.847045,"eighty":26.825987,"marketCap":10972800},{"date":"2024-12-13","current":18.931587,"twenty":15.475212,"median":20.935809,"eighty":26.444278,"marketCap":10749280},{"date":"2024-12-20","current":16.81288,"twenty":15.549996,"median":20.067961,"eighty":26.379894,"marketCap":9550400},{"date":"2024-12-27","current":7.581302,"twenty":15.240125,"median":20.023482,"eighty":26.25308,"marketCap":10741152},{"date":"2025-01-03","current":8.618162,"twenty":15.140189,"median":19.71984,"eighty":26.21899,"marketCap":12196064},{"date":"2025-01-10","current":10.05795,"twenty":14.800605,"median":19.685908,"eighty":26.181452,"marketCap":14224000},{"date":"2025-01-17","current":8.786233,"twenty":14.714645,"median":19.468094,"eighty":26.125394,"marketCap":12415520},{"date":"2025-01-24","current":9.780279,"twenty":10.25185,"median":19.354401,"eighty":26.087984,"marketCap":13817600},{"date":"2025-01-31","current":8.55813,"twenty":9.931507,"median":18.990258,"eighty":25.926183,"marketCap":12088368},{"date":"2025-02-07","current":8.034161,"twenty":9.67709,"median":18.942456,"eighty":25.806345,"marketCap":11354816},{"date":"2025-02-14","current":7.429972,"twenty":9.170381,"median":18.736365,"eighty":25.661057,"marketCap":10499344},{"date":"2025-02-21","current":7.182682,"twenty":8.786233,"median":18.611629,"eighty":25.398607,"marketCap":10166096},{"date":"2025-02-28","current":6.088957,"twenty":8.49005,"median":18.298903,"eighty":25.263582,"marketCap":8617712},{"date":"2025-03-07","current":6.285152,"twenty":8.101774,"median":18.113266,"eighty":25.252549,"marketCap":8900160},{"date":"2025-03-14","current":5.596631,"twenty":7.768683,"median":17.68941,"eighty":25.185699,"marketCap":7924800},{"date":"2025-03-21","current":6.28575,"twenty":7.480228,"median":17.54621,"eighty":25.06182,"marketCap":8900160},{"date":"2025-03-28","current":6.3175,"twenty":7.319362,"median":17.202773,"eighty":24.992177,"marketCap":8940800},{"date":"2025-04-04","current":6.433722,"twenty":7.066391,"median":16.81288,"eighty":24.761928,"marketCap":9104010},{"date":"2025-04-11","current":7.43656,"twenty":6.901399,"median":16.523806,"eighty":24.668714,"marketCap":10546080},{"date":"2025-04-17","current":5.733501,"twenty":6.823071,"median":16.327956,"eighty":24.52062,"marketCap":8128000},{"date":"2025-04-25","current":5.587097,"twenty":6.410478,"median":15.712059,"eighty":24.4461,"marketCap":7924800},{"date":"2025-05-01","current":4.935384,"twenty":6.301776,"median":15.60865,"eighty":24.382153,"marketCap":7002272}],"updateTime":1746200750553}}}